Navigation Links
Replidyne to Participate on Anti-infective Panel at RBC Capital Markets Healthcare Conference
Date:12/5/2007

LOUISVILLE, Colo., Dec. 5 /PRNewswire-FirstCall/ -- Replidyne, Inc. (Nasdaq: RDYN) announced today that President and Chief Executive Officer Kenneth J. Collins will participate on the New and Powerful Anti-infectives panel at the RBC Capital Markets 2007 Healthcare Conference. The panel discussion will take place at 11:00 am ET on Thursday, December 13, 2007 at the Westin Times Square in New York City.

A live audio webcast of the panel discussion will be available on the investor relations section of the company's website at http://www.Replidyne.com. The webcast will be archived and available on Replidyne's website after the event for a period of 30 days.

About Replidyne, Inc.

Replidyne is a biopharmaceutical company focused on discovering, developing, in-licensing and commercializing innovative anti-infective products. Replidyne's lead product, faropenem medoxomil, is a novel oral community antibiotic, expected to be appropriate for use as a first-line antibiotic for treatment of respiratory and skin infections in adult and pediatric patients. Replidyne's second drug candidate, REP8839, is a topical anti-infective product candidate in development for the treatment of skin and wound infections, including methicillin-resistant S. aureus (MRSA) infections. Replidyne's investigational antibacterial agent REP3123 targets Gram-positive C. difficile bacteria and C. difficile-associated disease (CDAD). Replidyne is pursuing the development of other novel anti-infective programs based on its in-house discovery research.


'/>"/>
SOURCE Replidyne, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Replidynes Investigational Antibacterial Agent REP3123 Prevents Sporulation in Clostridium difficile
2. Replidynes Investigational Antibacterial Agent REP3123 Prevents Toxin Production in Clostridium difficile
3. Georgia Reproductive Specialists Participates in Largest-Ever In Vitro Fertilization Clinical Trial in the World
4. Spit for the Cure Offers Unique Opportunity for Women to Participate in Breast Cancer Research
5. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
6. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
7. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
8. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
11. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... DUBLIN , Feb. 9, 2016  Jazz Pharmaceuticals ... will report its 2015 fourth quarter and full year ... close of the financial markets.  Company management will host ... 4:30 p.m. EST/9:30 p.m. GMT to discuss fourth quarter ... business and financial update and guidance for 2016 financial ...
(Date:2/9/2016)... February 9, 2016 Amarantus BioScience ... on developing products for Regenerative Medicine, Neurology and Orphan ... presenting company at Source Capital Group,s 2016 Disruptive Growth ... 2016 in New York City . ... 10, 2016 at 12:30 pm by Gerald E. ...
(Date:2/9/2016)... , Feb. 9, 2016 The new report "Global Blood Monitoring ... Acuity Business Research & Consulting group reveals that global market for ... million in 2014 and expected to grow to US$ 24,830.1 million ... North America , Europe ... , Middle-East and Africa ...
Breaking Medicine Technology:
(Date:2/9/2016)... ... February 09, 2016 , ... ... to expand access to affordable hearing aids , increase industry transparency, and ... in the United States. , “For the average consumer, the hearing aid industry ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... sealing company , is proud to announce that many of their franchises have ... customer service. The hard surface restoration franchises received customer recognition through positive reviews ...
(Date:2/8/2016)... ... 08, 2016 , ... The Federal Laboratory Consortium for Technology ... site houses a wealth of federal resources that businesses can leverage to further ... transfer (T2). As a network of over 300 federal laboratories, the FLC’s mission ...
(Date:2/8/2016)... ... ... who has struggled to quit smoking, a man who has struggled with hair loss – ... his problems – and he did. Now Nabat, a serial entrepreneur featured as the October ... to the world and better people's lives. His own experience with nicotine addiction led to ...
(Date:2/8/2016)... ... 2016 , ... The Bell Agency, a full service insurance ... their ongoing community enrichment program. The current campaign fundraises for Angels & Doves, ... being accepted at: http://www.angelsanddoves.com/donate.html . , Angels & Doves was founded in ...
Breaking Medicine News(10 mins):